drugset
drugset / Trial / NCT07001319

Study of GS-3242 in Participants With HIV-1; Substudy-05

NCT07001319 ↗

Phase 1 Completed 27 enrolled Gilead Sciences
NaSequentialOpen-labelTreatment

Summary

This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.

Timeline

Start
2025-05-29
Primary completion
2026-03-03
Completion
2026-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject GS-3242 Unknown 450 mg Oral
Background ABC Unknown — Oral
Background BVY Unknown — Oral
Background DTG Unknown — Oral
Background FTC Unknown — Oral
Background Lamivudine Other / unclassified — Oral
Background TAF Unknown — Oral
Background TDF Unknown — Oral

Indications

HIV infectious disease